本帖最后由 老马 于 2013-3-13 13:43 编辑
2 C4 v) S. t* x6 V G/ J+ O1 ]
7 v) h- j1 U* m7 G9 l; B- B- B+ h健择（吉西他滨）+顺铂+阿瓦斯汀
R. }+ [$ O, g' \/ t" g Gemzar +Cisplatin + Avastin
8 @4 ], s% g9 ^; G7 F& b) ^7 Hhttp://annonc.oxfordjournals.org/content/21/9/1804.full3 r: f3 K+ f7 m; H: v
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, N- ~. C* }* tPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ( Q' C7 m" N; U3 f0 F2 X+ c! d
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
) P ?: N% M# a* Q* I
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 611)
3 x' G8 X* D$ ?- P
华为网盘附件：' Z! M/ g( z5 P8 T* j
【华为网盘】ava.JPG
( ^- D v5 y1 I" h( d |
显身卡
